Most updated Research - Belong. Beating Cancer Together

Real Value Shared with the Global Community​

Revealing hidden patterns using Belong’s proprietary multilayered data powered by machine learning & artificial intelligence to advance clinical research and improve patient quality of life and care

Belong provides true value for the global community – for patients, caregivers, health professionals, providers and pharma.
We are deeply committed to helping advance the state of the treatment research with quality real world data.

Leveraging AI & ML
for a Hyper-Personalized Experience

Cutting-edge AI, machine learning and proprietary medical neural networks are transforming how partners understand patient journeys​

Why research with Belong?

Belong.Life Can Help You Accelerate Cancer Research

by understanding real-life treatment journeys, analyzing critical decision points, conducting surveys and providing you with competitive Business Intelligence.

Recent Studies

We have made a significant contribution with several research projects in the cancer arena. These have been published in leading international platforms.

2020

Real-world evidence data of financial toxicity in cancer patients receiving immunotherapy

Researched by Belong.Life and published by ESMO
Key Study to be Presented at ESMO Virtual Congress 2020 Shows Nearly Half of Patients Receiving Immunotherapy are Unaware of Possible Financial Toxicity (FT) Research Demonstrates Importance of Engaging Patients Throughout the Cancer Journey, Suggests Physicians Discuss FT from Moment of Diagnosis. Read More >

Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma

Researched by Belong.Life and Janssen published by JPRO
Social media platforms give patients a voice by allowing them to discuss their health and connect with others. These unfiltered and genuine reports offer direct access to what matters most to patients. Exploring the patient-reported outcomes discussed in these platforms reveal clinical insights and behavioural patterns of the real-world patient journey. This research study reviewed health-related quality of life (HRQoL) concepts reported by patients with multiple myeloma (MM).

"As the Belong.life platform is a constantly growing community with patients continuous reporting, it allows not only a growing evidence for detected concepts in many patients but also presents the possibility of following specific concepts through the full patient journey...Social listening can be utilized as a method in Patients Reported Outcomes (PRO) research and for further understanding of how concepts may change throughout the stages of a patients' journey". Read More >

Real-world evidence data (RWED) of financial toxicity (FT) in patients (pts) receiving cancer immunotherapy treatments.

Researched by Belong.Life and published by ASCO
RWED of financial toxicity was reported by the majority of cancer pts receiving Immunotherapy drugs for treatment of their solid tumors. 48% of the pts were aware of possible FTs as a result of their diagnosis and therapy. Only 36% received pre-treatment financial advice by their medical team and in those that received it, the FT incidence reported was reduced from 48% to 30% (absolute Down 37.5%) Physicians should be aware of their pts’s possible risks for FTs and relevant advice should be given prior to the immunotherapy drugs commencement. Read More >

Real-World data (RWD) of physician’s advice on BRCA genetic testing for ovary (OC) and breast cancer (BC) patients.

Researched by Belong.Life and published by ASCO
Key Findings : BRCA testing should be recommended for all pts with recently diagnosed BC and OC and in those with a higher chance of having a mutation, as defined by the USPSTF guidelines. In this RWD evaluation of Belong.life BC and OC pts, BRCA testing in BC was done in 192/302 pts (64%) while in OC pts it was done in 60/75 pts (80%). Overall, physicians requested the BRCA test in only 57% of BC pts and 76% of the OC pts. In spite of the current USPSTF guidelines, a number of BC pts who didn’t receive advise from their physician (32%) fell under those recommendations, most having their disease diagnosed at < 50 yrs and triple-negative disease & lt; 60 yrs. Physicians should be encouraged to follow published guidelines recommendations for BRCA testing for all newly diagnosed BC and OC pts. Read More >

Financial Toxicity (FT) Real-World Data Evidence (RWDE) In American Patients (Pts) Receiving Cancer Immunotherapy Drugs (IOT).

Researched by Belong.Life and published by ASCO
Key Findings: Financial toxicity is most prevalent in American patients older than 61. Half of those patients were unaware of possible issues of financial toxicity and only 29.3% received pre-treatment FT advice from their doctors. Those who did receive advice saw a 41% reduction in financial toxicity incidence. Read More >

Time From Diagnosis To 1st Line Immunotherapy (IOT) And Its Challenges, In A Retrospective, Multicenter Study Of Israeli Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC).

Researched by Belong.Life and published by ASCO
Key Findings: There is significant variability in the start of first line of treatment for Israeli patients diagnosed with advanced non-small cell lung cancer. This is most commonly due to the time it takes to obtain molecular test results to define targeted drugs. Treatment delays are likely to impact patient well-being negatively and developing a time to treatment protocol would be valuable. Read More >

2019

Implementation results at the gynecological cancer care in JGH​

Researched By Belong.Life with JGH and Presented by McGill University
See the latest study that was conducted by McGill University and the Jewish general hospital in Toronto, Canada, using the Belong.life platform. Read More >

a targeted survey of belong.life advanced breast cancer patients, focusing on patient’s reported outcomes, real world evidence and insights in reducing the burden of financial toxicity.

Researched by Belong.Life, Published by the The Breast.
In medicine, financial toxicity (FT) is a term used to describe economic problems a patient has related to the cost of medical care. Financial toxicity is an emerging and growing concern for many cancer patients Read More >

Real-world data (RWD) and patients reported outcomes (PRO) in breast cancer (BC): Physical, emotional side effects (S/E), financial toxicity (FT), and complementary usage (CM) relations.

Researched by Belong.Life and published by ASCO
RWD denotes data accumulated via electronic health records as well as cutting edge technology paired with consumer mobile devices. Artificial intelligence (AI) incorporates the use of algorithms and machine learning (ML) software to analyze complex medical data, improving the knowledge of cancer journeys. PRO on 256 BC patients (pts) survey repliers, users of Belong.life, a worldwide social media application for cancer pts, are presented. Read More >

Creating the real-world medical record: Using digital patient-generated data to create an updated picture of patients outcomes.

Researched by Belong.Life and published by ASCO
Value-based healthcare requires integration of real-world data (RWD) generated by patients in parallel to clinical documentation. This gives a holistic perspective of the patients’ health and care and could lead to reduced costs and better patient care and safety. Belong digital patient-powered network (PPN) is a social network for cancer patients and caregivers providing them access to other patients, healthcare professionals and disease management tools. In this study we compared the clinical data generated by Belong users with classical clinical documentation. Furthermore we explored the additional information generated in the PPN and its value. Read More >

Unveiling the real-world outcomes of breast cancer (BC) patients with taxanes-induced neuropathy using a digital patient-powered network (PPN).

Researched by Belong.Life and published by ASCO
Taxanes-induced neuropathy is common in BC patients receiving taxanes, forcing dose reductions and treatment delays and posing serious challenges for the long-term patient QoL. Discovering neuropathy predictors in patients could guide better treatment decisions, improved QoL and reduce healthcare costs. Belong digital PPN is a social network for cancer patients and caregivers that supports disease management. In this study we used our artificial intelligence (AI) engine to classify the prevalence, characteristics and taxanes-induced neuropathy status of BC patients. Read More >

2018

Mapping PD-1 inhibitors’ side effects using patient reported outcomes (PRO)

Researched by Belong.Life and published by ASCO
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes. Read More >

Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer​

Researched by Belong.Life and published by ASCO
Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer Data from patients using the Belong PPN was able to provide insights into the treatment journeys of MPC patients in Israel, the four firstline treatment prevalence and the following lines of treatment. Continuous evaluation of RWE and PRO from the Belong PPN would allow comparative effectiveness research of cancer treatments and lead to improved evidence-based care and patients’ health-related quality of life. Read More >

Fatigue prevalence and adherence to treatment: a real-world data survey and mathematical model application

Researched by Belong.Life and published by ASCO
Fatigue is a common symptom reported by cancer patients (pts) and has been previously documented to affect patient’s quality of life. A real-world data survey was designed to evaluate, from the pts perspective, the fatigue effect and treatment adherence. The survey was created in a digital format. This was sent randomly and replied anonymously by users of the Belong app a dedicated social network for cancer pts and their caregivers. Belong leveraged both push notifications as well as DPROs (Digital patients reported outcome feature) which appeared on user’s apps dashboards for their increased engagement. Read More >

New Cancer Patient Survey Shows Emotional Impact of Illness-Related Fatigue Greater than Physical Effect

Researched and published by Belong.Life
A real-world data survey was designed to evaluate, from the patients’ perspective, the effects of fatigue on their treatments as well as their emotional and physical state. Read More >